Semaglutide - Uses, Limitations, Dosage

Overview:

Semaglutide is the first and foremost drug by Novo Nordisk that the U.S. Food and Drug Administration (FDA) has sanctioned. Semaglutide has to be taken once a week and is formulated for chronic weight management. Additionally, Semaglutide is stipulated as an accompaniment to regular exercise and diet for chronic weight management in adults suffering from obesity or overweight with no less than one weight-related symptomatology such as high blood pressure, increased cholesterol levels, and type 2 diabetes.

Going through obesity or being overweight is a genuine health issue auxiliary to some significant death occasions, counting cardiovascular conditions, stroke, and diabetes. Furthermore, it is bracketed to an escalated risk of a specific category of cancer. Shedding 5 % to 10 % of body weight with diet and regular exercise has been analogous with a diminished risk of cardiovascular conditions in adult patients suffering from obesity or being overweight.

Glucagon-like peptide-1 (GLP-1) receptor agonist therapy has been studied and approved for weight management for people living with obesity. Semaglutide is the original glucagon-like peptide-1 (GLP-1) that is supposed to be taken once weekly. Semaglutide is 94 % similar to the body’s naturally occurring human glucagon-like peptide-1, and this is how it leads to an increased feeling of fullness, a reduced appetite that in turn helps people eat less, reduce their intake of calories, and lose weight.

Semaglutide functions by impersonating a hormone known as glucagon-like peptide-1 (GLP-1). Glucagon-like-peptide-1 earmarks those zones of the brain that synchronize intake of food as well as appetite control. The pharmaceutical dosage ought to be surged little by little within 16 weeks to 20 weeks to taper down the side effects manifesting in the gastrointestinal systems. Semaglutide should not be consumed in fusion with supplementary Semaglutide-containing products, other glucagon-like peptide-1 receptor agonists, or other products deliberated for weight loss and prescription drugs, over-the-counter drugs, or herbal products. Semaglutide has not been examined in patients with a history of pancreatitis.

Across the trial outcome in human beings who do not suffer from type 2 diabetes, a median weight loss of 17 % - 18 % assisted for 68 weeks was disclosed for people with obesity medicated with Semaglutide. In addition to this, Semaglutide exemplified a secure and well-tolerated portrayal beyond the program, with the most frequent unfavorable incidents being gastrointestinal.

Semaglutide’s safety and potency were measured in four 68-week trials. Three of those trials were double-blind, randomized, placebo-controlled trials (along with 16 weeks of dose escalation). One was a double-blind, randomized, placebo-control withdrawal trial in which patients received Semaglutide, resumed the treatment, or diverted to a placebo. More than 2,600 patients underwent Semaglutide for up to 68 weeks, and 1,500 secured placeboes within these four studies.

The substantial placebo-controlled trial registered adults unaccompanied by diabetes. At the beginning of the problem, the median age was 46 years, with 74 % of female patients. The mean body weight was 231 pounds or 105 kg, and the average body mass index was 38 kg/m2. People who accepted Semaglutide dropped 12.4 % of their primary body weight compared to individuals who received a placebo. An alternative trial enrolled adults who have type 2 diabetes. The median age was 55 years, and 51 % were female individuals. The mean body weight was 220 pounds or 100 kg, and the average body mass index was 36 kg/m2. In this trial, individuals who received Semaglutide dropped approximately 6.2 % of their primary bodyweight against those who received a placebo. Semaglutide has not been studied amongst those patients suffering from pancreatitis.

The most usual side effects of Semaglutide include the following:

• Nausea.

• Diarrhea.

• Vomiting.

• Constipation.

• Abdominal pain.

• Headache.

• Fatigue.

• Indigestion.

• Dizziness.

• Belching.

• Decreased blood sugar in patients with type 2 diabetes.

• Flatulence.

How Does Semaglutide Work?

Semaglutide is a glucagon-like peptide-1 receptor agonist. It escalates insulin production, a natural hormone that drops the level of blood sugar. It also gives the impression of intensifying the growth of beta-cells within the pancreas. The pancreas is the area of insulin manufacture. It also hampers glucagon. Glucagon is a hormone that increases the sugar content in the blood.

Furthermore, it limits the food intake because of inhibiting the appetite. It also decelerates digestion in the stomach and intestine. Due to all this, Semaglutide drops the body weight and body fat.

What Are the Uses of Semaglutide?

Below are the uses of Semaglutide:

• Glycemic control.

• Long-term weight loss.

• Obese weight management.

• Normalizing body mass index.

• Supplement with regular exercise to maintain weight.

• Additive to a healthy diet for reducing weight.

What Are the Limitations of Using Semaglutide?

• Semaglutide must not be used in union with a supplemental Semaglutide-containing drug or product.

• Any other glucagon-like-peptide-1 receptor agonist must not be used in adjunct with Semaglutide.

• It may not be prescribed for patients with pancreatitis since no study has been done on such patients with Semaglutide.

• Safety of administration along with any other weight loss supplement has not yet been official.

What Are the Dosage and Administration Instructions for Semaglutide?

The most vital criteria before prescribing Semaglutide is to select the right patient. Patient selection is important because the mechanism of action for Semaglutide is set for only a specific agonist, as mentioned above. Patient selection is based more or less on the body mass index and their weight loss plan. Semaglutide is used as a supplement for patients who are on a calorie deficit diet and those who involve themselves in regular physical activities. Body mass index is calculated by dividing an individual's weight in kilograms by their height in meters squared. A body mass index chart is suitable to determine the same. Semaglutide is strongly recommended for patients with a body mass index of the following:

• 30 kg/m2 or more - Corresponding to obesity.

• 27 kg/m2 or more - Corresponding to overweight.

• Overweight and comorbidities related to weight such as type 2 diabetes or hypertension.

Semaglutide should be started with a small dose of 0.25 mg in subcutaneous injection, jabbed once a week. The quantity is then shot up as the weeks go by. Below are the dose escalations to cut back on any adverse reaction to the gastrointestinal system.

• 0.25 mg for the first four weeks.

• 0.5 mg from the fifth to the eighth week.

• 1 mg through the ninth and twelfth week.

• 1.7 mg through the thirteenth and sixteenth week.

• A maintenance dose of 2.4 mg from week 17 onwards.

There are some critical points that the patient's caretaker should keep in mind during the administration of Semaglutide. Mentioned below are some of them.

• In case the patient is self-injecting, they must be trained adequately. The same applies to the family member or caretaker, or whoever is performing the subcutaneous injection. It is advised to always go through instructions and illustrations mentioned inside the drug’s packaging.

• Evaluate Semaglutide before injection for any particles. Ideally, the injection should be a colorless and transparent solution.

• Semaglutide can be administered before or after food, but it should be kept in mind that the injection should be given on the same day of the week regardless of the timing. The preferable sites are the thigh, upper arm, or abdomen. These sites can be interchanged as per the patient's comfort.

• Inject Semaglutide immediately in the event of missing a dose, with the next scheduled dose having a gap of more than 48 hours. In case the next dose is less than 48 hours, do not administer the missed dose.

• In case more than two doses are continuously missed, resume the next dose or restart the dose escalation. The healthcare provider best takes this decision.

• If the patient suffers from gastrointestinal side effects due to dose escalation, contemplate delaying the escalation for another four weeks.

• If the patient is not well tolerating the maintenance dose, it can be brought down to 1.7 mg as per the dose-escalation above. After four weeks, the maintenance dose is once again initiated, and if the patient is yet not able to tolerate it, the maintenance dose is eliminated.

• Blood glucose levels must continually be monitored before initiating Semaglutide and randomly during the treatment with Semaglutide.

When Is Semaglutide Contraindicated?

Mentioned below are the scenarios as and when Semaglutide has been contraindicated.

• A medullary thyroid carcinoma or MTC history runs in the family or any individual in the family.

• Family history or patients were suffering from multiple endocrine neoplasia syndrome type 2 or MEN 2.

• An episode of anaphylaxis to Semaglutide that had occurred in the past.

• An episode of angioedema to Semaglutide had happened in the past.

What Are the Adverse Reactions of Semaglutide?

Warning: There Is a Risk of Thyroid C-Cell Tumors.

Clinical trials are conducted under a wide range of conditions. Semaglutide forms an opinion of being safe in three double-blind, randomized, placebo-controlled trials that comprised 2116 patients. These patients were overweight or obese and underwent treatment with Semaglutide for straight 68 weeks, along with seven weeks of the drug investigation. The average baseline characteristics in the trial included 71 % women, 42 % of hypertensive patients, 19 % with type 2 diabetes mellitus, 28 % with a body mass index greater than 40 kg/m2 corresponding to obesity, and 4 % with cardiovascular conditions. Forty-eight years was the mean age of the individuals in the trial. 6.8 % of the patients treated with Semaglutide discontinued it in perpetuity due to adverse reactions. The most frequent adverse reaction that led to this discontinuation was because of nausea and vomiting. The adverse reactions to Semaglutide are mentioned below in detail.

• Thyroid C-Cell Tumors - The risk of thyroid c-cell tumors (carcinomas and adenomas) had been exposed to rats and mice after Semaglutide treatment. Additionally, there have been cases of medullary thyroid carcinoma in humans treated with another glucagon-like-peptide-1 receptor agonist called Liraglutide. Thus, evidence of developing thyroid c-cell tumor in rats and medullary thyroid carcinoma in similar agonists, putting individuals at risk of developing the conditions as mentioned earlier. There has not been a substantial determination of human relevance in Semaglutide-activated rodent tumors.

• Acute Pancreatitis - Cases of acute pancreatitis in clinical trials, those that are fatal as well as non-fatal, have come into evidence post-treatment with glucagon-like-peptide-1 receptor agonists, specially Semaglutide. After a patient starts treatment with Semaglutide, an eye should be kept for acute pancreatitis clinical manifestations before the case worsens. In case there has been a definite diagnosis of acute pancreatitis, Semaglutide must be immediately discontinued. In Semaglutide trials, four patients treated with Semaglutide had confirmed acute pancreatitis. On the other hand, only one placebo-treated patient was confirmed with acute pancreatitis.

• Gallbladder Diseases - Incidences of acute gallbladder diseases such as cholelithiasis and cholecystitis have been reported in clinical trials of patients treated with Semaglutide as well as placebo-treated individuals. The weight lost quickly over a short time can lead to cholelithiasis. Furthermore, it has been documented after clinical trials that the occurrence of gallbladder disease is more remarkable in the number of individuals who underwent Semaglutide treatment. In Semaglutide trials, 1.6 % of Semaglutide treated patients confirmed the presence of cholelithiasis against 0.7 % of placebo-treated patients. There were also 0.6 % of Semaglutide patients who confirmed cholecystitis and 0.2 % of placebo-treated patients with the same disease.

• Severe Hypoglycemia - It has been established that Semaglutide drops the glucose content in the blood and thus leads to hypoglycemia. In clinical trials of patients who have type 2 diabetes, hypoglycemia has been reported. In patients with a body mass index corresponding to being overweight, plasma glucose reduction has been reported. There has been an episode of severe hypoglycemia in a Semaglutide-treated patient. Patients who are suffering from type 2 diabetes mellitus and are already taking Insulin, after additional treatment of Semaglutide developed an increased risk of severe hypoglycemia. Thus patient education about the signs and symptoms of hypoglycemia is crucial. Patients who suffer from type 2 diabetes Mellitus and those who underwent Semaglutide trials reported 6.2 % of hypoglycemic confirmations against 2.5 % placebo-treated patients with the same assurance. These individuals also had a body mass index corresponding to being overweight.

• Acute Kidney Injury - In some patients treated with Semaglutide, there are reports of worsening chronic renal failure as well as kidney injuries. Patients who suffer from an underlying renal impairment are at a higher risk of kidney damage in case they decide to treat with Semaglutide. There has also been evidence of patients developing acute kidney failure after initiating treatment with Semaglutide, even if they do not necessarily have any history of renal impairment. The renal function should be monitored continuously after escalating the dose of Semaglutide. Seven patients were confirmed with acute kidney injury in Semaglutide trials. These patients underwent Semaglutide treatment. Placebo patients were also assured with acute kidney failure, but only a mere four patients. Acute kidney failure due to dehydration has also been reported in other clinical trials amongst patients treated with Semaglutide. After clinical trials, it has been documented that the risk of adverse effects in the renal system is higher in patients with a history of renal dysfunction that is moderate to severe.

• Hypersensitivity - Cases of anaphylaxis and severe angioedema have been reported with Semaglutide. In case there are signs and clinical manifestations of the initiation of anaphylaxis or any other hypersensitivity. Semaglutide must be immediately discontinued, and prompt management should be sought after. Patients with a long history of angioedema or anaphylaxis should cautiously start treating themselves with Semaglutide because such cases of hypersensitivity have also been reported in other glucagon-like-peptide-1 receptor agonists.

• Diabetic Retinopathy - Complications of diabetic retinopathy in Semaglutide clinical trials have been seen only in patients with type 2 diabetes mellitus and those with a body mass index corresponding to being overweight. The absolute risk of developing severe diabetic retinopathy after treatment with Semaglutide is higher in patients with type 2 diabetes mellitus who already have a history of diabetic retinopathy. Patients who were overweight and suffered from diabetes mellitus participated in clinical trials, giving results that retinal disorders did occur in 6.9 % of patients who underwent Semaglutide treatment as compared to placebo patients with only 4.2 % occurrence of retinal impairment.

• Increase in Heart Rate - A median increase in the heart rate of 1 to 4 beats per minute has been observed in Semaglutide-treated patients in clinical trials. The maximum change in the baseline of heart rate ranges from an excess of 10 beats to 19 beats per minute. The patient should be instructed and educated about the increase in heart rate and to inform their health care provider of any alterations in heart rate if experienced after Semaglutide treatment.

• Altered Mental Behavior - Clinical trials with patients undergoing weight management and using Semaglutide and other weight management products have reported showing signs of depression, suicidal thoughts, unusual mood alterations, and worsening of the present depression. Semaglutide should be stopped immediately if patients reveal altered mental states such as suicidal tendencies or suicidal attempts. More frequent adverse effects of Semaglutide include- vomiting, constipation, abdominal pain, headache, fatigue, dizziness, rashes, hypotension, syncope, hair loss, and GERD or gastroesophageal reflux disease.

How Does Semaglutide Interact With Other Drugs?

Semaglutide drug interactions have been studied with Insulin and some oral medications.

• Semaglutide, if taken along with Insulin or Insulin secretagogues such as sulfonylureas, decreases the glucose content of blood and may thus lead to hypoglycemia. This is one of the reasons why Semaglutide should be taken with strict consideration if it is combined with Insulin.

• Semaglutide has the potential to delay the emptying of the stomach. This will evidently have a substantial impact on the absorption of oral medications. Nevertheless, it has been shown in clinical trials that Semaglutide does not affect the absorption of oral drugs or over-the-counter drugs.

How Can Semaglutide Be Used in Pregnancy?

Pregnant women generally have a pregnancy exposure registry that praepostor pregnancy consequences in women who have come in contact with Semaglutide. Semaglutide should be discontinued two months before planning to get pregnant. This is due to the reproductive potential of Semaglutide and its long half-life.

• Based on studies, there seems to be a flair in potential risks associated with the fetus after being exposed to Semaglutide.

• It should also be kept in mind that weight loss does not add to any benefit to pregnant ladies and may actually backfire and cause harm to the fetus.

• There are insufficient proofs and records to link any congenital disability, miscarriage, or adverse effect to the fetus after coming in contact with Semaglutide due to the mother.

• Nevertheless, some pharmacological evidence suggests discontinuing the use of Semaglutide once pregnancy is confirmed to steer away from any possibility of fetal suffering.

How Can Semaglutide Be Used During Lactation?

Semaglutide has been found in rat milk during experiments. Currently, there is no clinical data available on the existence of Semaglutide or its metabolites in human milk or the creation of human milk. The advantages of fetus health and fetal development because of breastfeeding are taken into consideration in addition to the mother’s requirement for Semaglutide. Also, when a drug is present in the milk of an experimental animal, it is highly possible to be present in human milk as well but in 3 to 12 times lower plasma levels.

Can Semaglutide Be Used in Pediatrics and Geriatrics?

The potency and safety of Semaglutide have not been studied, and thus it has not been established for patients between 65 years and 75 years. Overall safety and adequacy are no different from patients of younger age groups. It should not be ignored that elderly patients are generally more sensitive to any form of the drug. Thus, this point must not be ruled out while treating the senior group with Semaglutide.

What Are the Signs of Semaglutide Overdosage?

Not only Semaglutide overdose but also overdose of other glucagon-like-peptide-1 receptor agonists have been documented. Vomiting, diarrhea, nausea, and severe hypoglycemia are some of the clinical manifestations that a patient is undergoing a Semaglutide. In such an event, the line of treatment should be by addressing the signs and symptoms first. This is done in addition to the knowledge of the half-life of Semaglutide.

Semaglutide - For Doctors

Warning: There Is a Risk of Thyroid C-Cell Tumors.

What Is Semaglutide?

Semaglutide is an injection for subcutaneous administration. Semaglutide is a sterile, explicit, colorless, aqueous collusion. It was manufactured by Novo Nordisk and received its initial U.S. Approval in 2017. Semaglutide has an approximate pH of 7.4. In order to adjust the pH level, sodium hydroxide or sodium chloride may be mixed. A single dose pen of 0.5 ml consists of a Semaglutide solution that comprises 0.25 mg, 0.5 mg, or 1 mg Semaglutide. On the other hand, if the single-dose pen is 0.75 ml, it will include 1.7 mg or 2.4 mg of Semaglutide. 1 ml of Semaglutide is a combination of the following inactive substances:

• 1.42 mg of disodium phosphate dihydrate.

• 8.25 mg of sodium chloride.

• Water.

Semaglutide injection consists of Semaglutide, which is a human glucagon-like-peptide-1 receptor agonist or glucagon-like-peptide-1 analog. The backbone of this peptide is created after the fermentation of yeast. The chief apparatus for protraction of Semaglutide is binding albumin that has been made easier due to the mitigation of 26 lysine position and a spacer that is hydrophilic in nature and a C18 fatty di-acid. Moreover, Semaglutide is recast in position 8 to impart remodeling at odds with debasement by DPP-4 or the enzyme dipeptidyl-peptidase 4. A trivial alteration was made in position 34 to set the seal on the adjunct of specifically a single fatty di-acid. The molecular weight and the molecular formulae are 4113.58 g/mol and C187H291N45O56, respectively.

What Is the Mechanism of Action of Semaglutide?

Semaglutide is a glucagon-like-peptide-1 analog with approximately 94 % homologous sequence to human glucagon-like-peptide-1. Semaglutide behaves as a glucagon-like-peptide-1 receptor agonist that judiciously links to as well as ignites the glucagon-like-peptide-1 receptor, which is the supreme target for native glucagon-like-peptide-1.

Glucagon-like-peptide-1 is a physiological push button or regulator of calorie intake and appetite. Glucagon-like-peptide-1 is available in various brain zones that form an intricate complex with the regulation of appetite. Studies on animals have proven that Semaglutide disseminated to and reignited the neurons in brain areas that are straightforward in regulating the intake of food.

What Are the Pharmacodynamics of Semaglutide?

Semaglutide reduces the body's overall weight by lowering the intake of calories. Such effects are more or less impacted due to the impact of appetite. Semaglutide additionally invigorates insulin secretion, which is parallel to other glucagon-like-peptide-1 receptor agonists. Semaglutide takes the edge off glucagon secretion in a glucose-dependent manner. All these repercussions can result in a reduction of the level of glucose in the blood. A QTc trial was conducted to check the consequence of Semaglutide in the cardiovascular system. There was no change in the cardiac repolarization, and neither was there any elongation of the QTc intervals, even at a dose of 1.5 mg.

What Are the Pharmacokinetics of Semaglutide?

There are pharmacokinetic results of Semaglutide on aspects of absorption, distribution, elimination, metabolism, and excretion.

• Absorption - Semaglutide has an absolute bioavailability of 89 %. The topmost concentration of Semaglutide is outstretched to 3 days after dose administration in the thigh, upper arm, or abdomen. The main steady-state concentration of Semaglutide after a subcutaneous administration was roughly 75 nmol/L. This is mainly in patients with a body mass index corresponding to obesity or being overweight. As the dose of Semaglutide is turned up, the stated results also increase.

• Distribution - The average distribution volume of Semaglutide after the administration of subcutaneous injection in patients who are obese or overweight is roughly 12.5 liters. Semaglutide colossally is cavorted to plasma albumin more than 99 %. This leads to a fall in renal clearance as well as defending from degradation.

• Elimination - Semaglutide will still be available in the circulatory system for approximately 5 to 7 weeks post the last dose or maintenance dose of 2.4 mg. Also, the half-life elimination is roughly seven days. The perceptible clearance of Semaglutide in obese or overweight patients is around 0.05 l/h.

• Metabolism - The principal pathway to extinguish Semaglutide is metabolism, followed by the cleavage of the proteolytic of the peptide backbone as well as a sequential beta-oxidation of the fatty acid sidechain.

• Excretion - The chief circuit of Semaglutide and Semaglutide-related substances is through urine and feces. Roughly 3 % of Semaglutide dose is discharged in the urine as unscathed Semaglutide.

How Immunogenic Is Semaglutide?

Most protein and peptide pharmaceuticals are immunogenic. Parallel to this, Semaglutide also has immunogenic properties of high potential to produce anti-Semaglutide antibodies. It has also been observed that Semaglutide can trigger the production of neutralizing antibodies. There have been multiple clinical trials with reports that show 2.9 % Semaglutide treated patients had developed ADA or anti-drug antibodies. The sensitivity of the assay is one of the strong paths to determining and detecting any antibody formation. There are multiple factors to find out if an antibody is being developed in the body.

Some of such factors include:

• The method of assay.

• The way the sample is handled.

• The time of collecting the sample.

• Concomitant medications.

• Presence of any underlying condition.

What Are the Nonclinical Toxicology Aspects of Semaglutide?

• In a 2-year long carcinogenicity study in mice, subcutaneous doses of 0.3, 1, and 3 mg/kg/day were administered in males. On the other hand, the dose administered to females were 0.1, 0.3, and 1 mg/kg/day. An authentically remarkable surge in thyroid c-cell adenomas and an integral swell in c-cell carcinomas were discerned in both males and females at all levels of the doses. This is greater than or equal to 0.6 times the exposure to humans.

• An analytically notable climb in thyroid c-cell adenomas was perceived in males and females at all levels of doses. This was also the case for the presence of thyroid c-cell carcinomas. A similar study was done on Sprague Dawley rats but with lower amounts of 0.0025, 0.01, 0.025, and 0.1 mg/kg/day.

• The applicability of thyroid c-cell tumors in rats and humans is not clear, and it cannot be established just by clinical trials or nonclinical studies. Semaglutide was not found to be mutagenic or clastogenic in a typical battery of genotoxicity tests or bacterial mutagenicity.

• In an amalgamated fertility study of rats, subcutaneous doses of Semaglutide were injected. Males were administered four weeks before the gestation period, and females were administered two weeks prior to the gestation period. The result of the trial- no changes were observed in the fertility of males. In females, elongation in the estrous cycle length was noticed. It is understood that the weight of the body and food consumption play a crucial pharmacological role in the fertility of males and females under Semaglutide.

What Is the Overview of Clinical Studies Done With Semaglutide?

To substantiate the harmlessness and potency of Semaglutide in favor of chronic weight management. i.e., weight maintenance and weight loss, in concomitance with a controlled intake of calories and improved physical activity, studies of three 68 weeks double-blind, placebo-controlled, randomized trials were conducted. Additionally, a single 68 weeks double-blind placebo withdrawal randomized trial had also been conducted.

In trials 1, 2, and 3, Semaglutide or a similar placebo was shot up to 2.4 mg once a week, subcutaneously in the 16 weeks, and this was followed by 52 weeks of maintenance dose. In trial 4, Semaglutide was increased within a 20 week run-in period. Patients who had touched Semaglutide 2.4 mg post the run-in periods were randomized to continue with the treatment of Semaglutide or continue with the placebo for 48 weeks.

The segment of patients who ceased the study in trials 1, 2, and 3 was approximately 16 % of the Semaglutide treated group. The placebo-treated group that discontinued was 19.1 %. Amongst these two groups, adverse effects were the reason left for 6.8 % of Semaglutide treated individuals and 3.2 % of placebo-treated individuals. In trial 4, 5.8 % of Semaglutide treated patients discontinued, and 11.6 % of placebo-treated patients ceased the prosecution.

In the trial groups of 1, 2, and 4, the individuals were instructed to limit their calorie intake and maintain a calorie deficit of 500 kcal per day. They were also introduced to start with regular exercise. All the individuals in this group had a body mass index corresponding to obesity. They were then treated with the first dose of Semaglutide along with the above instructions. In the trial, three individuals were instructed to follow a reduced-calorie diet for eight weeks that includes a daily calorie intake of 1000 kcal per day. After 60 weeks, they were allowed to maintain their calorie intake per day to 1200 kcal. This was accompanied by the instruction to increase their physical activities and also receive the first Semaglutide dose. A depletion of 12.4 % of body weight was remarked with Semaglutide, notwithstanding race, age, sex, body mass index, or ethnicity.

What Are the Cardiovascular Outcomes of Semaglutide in Patients With Type 2 Diabetes and Cardiovascular Disease?

Semaglutide 0.5 mg and Semaglutide 1 mg have been used to treat patients with type 2 diabetes mellitus in adults. The potency of these two doses of Semaglutide has not yet been established for the management of chronic weight loss.

A 104 weeks, double-blind trial that included 3297 patients suffering from type 2 diabetes and atherosclerosis cardiovascular disease was randomized to Semaglutide 0.5 mg once a week, Semaglutide 1 mg, once a week again, or placebo along with standard-of-care for an average study observation period of 2.1 years. Out of all, 83 % of the participants presented with a history of cardiovascular condition, and amongst them, 17 % were at an increased risk of an unknown cardiovascular illness. The average age of the individuals was 65 years, with 61 % males. 83 % of the participants were White, 7 % were African American, and 8 % were of Asian descent. Hispanics and Latinos comprised 16 %.

At the end of the trial, the vital reports of 99.6 % of participants were collected. The central composite endpoint was the period that starts from randomization to the first occurrence of a MACE or major adverse cardiovascular event such as cardiovascular collapse, non-fatal stroke, and non-fatal myocardial infarction. With Semaglutide, no risk of major adverse cardiovascular events was reported.

How Is Semaglutide Stored and Handled?

Semaglutide injection is a colorless and clear solution that comes in a pre-filled, disposable, single-dose pen injector with a fused needle. Before the removal of the cap, the pen can be held at 8 degrees to 30 degrees for 28 days. This single-dose pose is suggested to be stored in a refrigerator that has a temperature ranging from 2 degrees Celsius to 8 degrees celsius.

• Semaglutide must not be frozen.

• Semaglutide must be protected from light.

• Semaglutide pen must be discarded after use.

What Should the Patient Be Counseled About Before Prescribing Semaglutide?

Before prescribing any patient Semaglutide, an overall assessment of the health status, underlying conditions, history of cancer or related diseases, as well as body mass index should be documented. The patient's physical activeness and willingness to maintain ideal weight should also be taken into account. Below is the crucial counseling information that needs to be addressed to the patient.

• Risk of thyroid c-cell tumors.

• Acute pancreatitis.

• Acute gallbladder diseases.

• Hypoglycemia.

• Dehydration.

• Renal impairment.

• Hypersensitivity.

• Diabetic retinopathy.

• Increased heart rate.

• Suicidal intentions.

• Depression.

• Fetal harm if pregnant or planning for pregnancy.

Pregnant patients who have already exposed themselves to Semaglutide are suggested to report the same to Novo Nordisk.

Semaglutide - For Patients

Warning: There Is a Risk of Thyroid C-Cell Tumors.

What Are the Most Important Instructions for Semaglutide?

• Always read the entire medication guide provided before use and each time a refill is done.

• Semaglutide has a possible risk of thyroid tumor as well as cancer.

• Healthcare providers must be informed of any lump in the neck, swelling, hoarseness of voice, trouble in swallowing, or shortness of breath since these may be the clinical manifestations of throat cancer.

• Avoid Semaglutide if there is a family history of medullary cancer or any endocrine system abnormality such as MEN 2 or multiple endocrine neoplasia syndrome type 2.

What Is Semaglutide?

Semaglutide is a prescription medicine that comes in an injectable form. It is manufactured in Denmark at the facility of Novo Nordisk. Semaglutide is for adults who are obese or overweight and plan to lose weight. These patients also suffer from weight-related issues such as heart problems or breathing problems. Semaglutide, in short, is a supplement for obese and overweight individuals who are already suffering from weight-related diseases, mainly type 2 diabetes. This supplement, along with regular exercise and decreased calorie intake, has proven to help in weight loss management.

When To Not Use Semaglutide?

Semaglutide is an injectable prescription drug to help obese and overweight individuals to shed extra pounds or keep the excess weight off.

• Semaglutide should not be used along with another similar composition drug.

• Semaglutide should not be used with herbal or ayurvedic medicines.

• Semaglutide should not be used with any over-the-counter medication.

• Semaglutide should not be used by individuals below the age of 18 years.

• Semaglutide should not be used by people who have a history of pancreatitis.

The healthcare provider will prescribe Semaglutide to only specific individuals after vigorous history examination and bearing in mind the adverse effects of Semaglutide. An individual must inform their healthcare provider about any of the following:

• A family history of thyroid cancer.

• A family history of any cancer.

• Any present or past endocrine disease in the family.

• Any episode of allergic reaction to any drug.

• Recent hospitalization and the reason for the same.

• Any sensitivity that led to swelling of the face lips.

• Any sensitivity that resulted in rashes and hives on the skin.

• Any recent episodes of shortness of breath or increased heart rate.

• Current problems with the pancreas or kidneys.

• A history of diabetes and diabetic retinopathy.

• Any mental ailment or emotional distress.

• Any underlying cardiovascular condition.

• Plans to become pregnant in the coming days.

• Currently breastfeeding or plans to breastfeed.

• Any over-the-counter medications or any other drugs that are being taken now.

• Administration of insulin or sulfonylureas.

In case a pregnant patient has already exposed themselves to Semaglutide, she must register herself to the pregnancy exposure registry Novo Nordisk.

How to Use Semaglutide?

• Always read all the instructions in the packaging.

• Use Semaglutide only as instructed by the healthcare provider.

• Ask the healthcare provider to show the way to use Semaglutide.

• Semaglutide can be administered before or after food.

• Semaglutide is injected under the skin of the thigh, upper arm, or stomach. It must never be injected into a blood vessel or muscle.

• The same site of injection must not be used again and again.

• Semaglutide should be administered once a week on the same day of the week, regardless of the time of the day.

• Start Semaglutide only as per the dose instructed by the healthcare provider. The healthcare provider will increase the quantity as necessary. Do not increase or alter the amount on your own.

• Inject Semaglutide immediately in the event of missing a dose, with the next scheduled dose having a gap of more than 48 hours. In case the next dose is less than 48 hours, do not administer the missed dose.

• In case more than two doses are continually missed, resume the nest dose or restart the dose escalation. The healthcare provider best takes this decision.

• If the patient suffers from gastrointestinal side effects due to dose escalation, contemplate delaying the escalation for another four weeks.

• Post administration of Semaglutide, episodes of nausea, severe vomiting, and a drastic drop in blood sugar should be promptly alerted to the healthcare provider or the nearby emergency service.

What Are the Side Effects of Semaglutide?

Semaglutide must be immediately stopped in case there is an experience of abdomen pain, severe vomiting, severe nausea, or pain in the back that does not go away. The healthcare provider must be immediately informed about the same.

Below is the list of the side effects that should be addressed and not ignored.

• Pain in the upper abdomen.

• Yellowish discoloration of the skin and eyes.

• Fever.

• Clay-colored stools.

• Light-headedness.

• Blurred vision.

• Anxiety.

• Depression.

• Feeling jittery.

• Headache.

• Weakness.

• Shakiness.

• Slurred speech.

• Drowsiness.

• Confusions.

• Sweating.

• Mood changes.

• Irritability.

• Sadness.

• Dehydration.

• Increased thirst.

• Severe Vomiting.

• Severe Diarrhea.

There are chances of severe allergic reactions that need medical help immediately. Below are some of the clinical manifestations that require immediate attention and prompt treatment.

• Swelling of the face, lips, and tongue.

• Rashes.

• Itching.

• Rapid heartbeat.

• Sore throat.

• Difficulty swallowing.

• Fainting or syncope.

• Vision changes in patients with diabetes.

• Pounding feeling in the chest.

• Suicidal intentions.

The most common side effects of Semaglutide that are not very problematic and do not need medical attention include the following below:

• Nausea.

• Diarrhea.

• Vomiting.

• Constipation.

• Abdominal pain.

• Headache.

• Fatigue.

• Indigestion.

• Dizziness.

• Belching.

• Flatulence.

What Are the Ingredients in Semaglutide?

• Active constituent: Semaglutide.

• Inactive constituents: Sodium chloride, disodium phosphate dihydrate, and water.

What Are the Strengths of Semaglutide?

Semaglutide injection comes in five strengths-

• 0.25 mg / 0.5 ml.

• 0.5 mg / 0.5 ml.

• 1 mg / 0.5 ml.

• 1.7 mg / 0.75 ml.

• 2.4 mg / 0.75 ml.

How to Store Semaglutide?

• Store the Semaglutide pen in the fridge between a temperature of 2 degrees Celsius to 8 degrees Celsius or 36 degrees Fahrenheit to 46 degrees Fahrenheit.

• Before removing the cap of the injectable Semaglutide, the pen can be stored for up to 28 days at a temperature of 8 degrees Celsius to 30 degrees Celsius or 46 degrees Fahrenheit to 86 degrees Fahrenheit.

• Semaglutide should be protected from light, so keeping it in the original packaged carton is suggested.

• Semaglutide must not be frozen.

• Discard the Semaglutide pen in case it is frozen or has been exposed to light or above the temperature of 30 degrees Celsius or 86 degrees Fahrenheit.

• Keep Semaglutide and all other medications away from children.

All instructions provided in this article have been approved by the U.S. Food and Drug Administration